



Broker Briefing Investor Webinar

7 September 2021 – Perth, Australia: PharmAust Limited (ASX: PAA), a clinical-stage biotechnology company, is pleased to advise shareholders and investors that the Company will be presenting as part of the free Broker Briefing Tech & Biotech Investor Webinar on Thursday 9 September 2021.

Date: 9 September 2021

Time: 11:30am AEST / 9:30am AWST

Presenter: Chief Scientific Officer, Dr Richard Mollard, presenting at 11:50am AEST / 9:50am AWST

The Company invites shareholders, investors, and media to participate in this digital event by registering online via the link below:

https://zoom.us/webinar/register/7516308952354/WN_CvohbgPISfOEz1d2hdaQzg

Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to info@brokerbriefing.com

This ASX release has been approved for release by Sam Wright on behalf of the Board of Directors.

Enquiries:

Sam Wright
Finance Director
sam@pharmaust.com

About PharmAust (PAA):

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated \$2.2 million in revenue in FY 2021.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.